![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » House Approves Tax Bill that Ends Orphan-Drug Credit
House Approves Tax Bill that Ends Orphan-Drug Credit
![](https://www.fdanews.com/ext/resources/test/Device_Images6/TaxSittingonCoins.gif?t=1489667166&width=430)
A sweeping tax overhaul bill approved by the House in a 227-205 vote Thursday would eliminate the orphan-drug tax credit, although the version of the legislation up for Senate consideration wouldn’t go that far.
The orphan drug provision in current law allows drug manufacturers to claim a credit equal to 50 percent of the costs of any human clinical testing conducted in the development of a drug for a rare disease, defined by the FD&C Act as a condition affecting fewer than 200,000 people in the U.S.
The congressional Joint Committee on Taxation estimates the removal of the credit, effective Jan. 1, 2018, would increase tax revenues by $54 billion over 10 years.
Upcoming Events
-
21Oct